Find out how Orsiro Mission can benefit your daily practice.

LEARN MORE
Principal investigator of the BIOSTEMI-ES Trial presents 5-year results

Juan F. Iglesias, MD, Geneva, Switzerland

Principal investigator of the BIOSTEMI-ES Trial presents 5-year results

Juan F. Iglesias, MD, Geneva, Switzerland

DAPT_Proven Safety

Proven Safety and Efficacy with 1-month DAPT.**,4​​​​​​​

DAPT=dual antiplatelet therapy; HBR=high bleeding risk; STEMI = ST-Elevation Myocardial Infarction

*Target Lesion Failure at 5-year follow-up Orsiro DES: 7.7%  Xience DES: 11.1% BIOSTEMI with historical information RR, 0.70; 95% BCI, 0.51-0.95, Bayesian posterior probability, 0.988 Difference: -31%. **Orsiro Mission DES is not indicated for one month of dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients. Please refer to the IFU for indications and post-procedure antiplatelet therapy recommendations.  

1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. BIOTRONIK data on file. Status February 2023; 3. Iglesias, JF. Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the BIOSTEMI Randomized Trial, Presented at: TCT 2023; October 25, 2023; San Francisco, USA; 4. Valgimigli M. et al. Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial, Circulation, 2023.

Clinical data collected with either Orsiro DES or Orsiro Mission DES device within the Orsiro family clinical program.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies. All other trademarks are the property of their respective owners.

© 2024 BIOTRONIK AG – All rights reserved.   
Specifications are subject to modification, revision and improvement.